Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) – Investment analysts at Cantor Fitzgerald cut their FY2017 earnings per share estimates for shares of Aldeyra Therapeutics in a research note issued on Sunday. Cantor Fitzgerald analyst E. Piros now expects that the biotechnology company will post earnings of ($1.34) per share for the year, down from their previous forecast of ($1.30). Cantor Fitzgerald currently has a “Overweight” rating and a $22.00 target price on the stock.

A number of other equities research analysts have also weighed in on the company. Zacks Investment Research upgraded Aldeyra Therapeutics from a “sell” rating to a “buy” rating and set a $6.75 price objective on the stock in a research report on Tuesday. ValuEngine lowered Aldeyra Therapeutics from a “hold” rating to a “sell” rating in a research report on Tuesday, September 26th. Cowen and Company reaffirmed an “outperform” rating and set a $14.00 target price (up from $9.00) on shares of Aldeyra Therapeutics in a report on Thursday, September 14th. Canaccord Genuity reaffirmed a “buy” rating and set a $27.00 target price (up from $12.00) on shares of Aldeyra Therapeutics in a report on Wednesday, September 13th. Finally, HC Wainwright set a $18.00 target price on Aldeyra Therapeutics and gave the stock a “buy” rating in a report on Wednesday, August 9th. One investment analyst has rated the stock with a sell rating and six have issued a buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus price target of $17.29.

ILLEGAL ACTIVITY NOTICE: “Cantor Fitzgerald Equities Analysts Decrease Earnings Estimates for Aldeyra Therapeutics, Inc. (ALDX)” was published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this story on another domain, it was stolen and republished in violation of United States and international copyright law. The original version of this story can be accessed at https://www.thecerbatgem.com/2017/11/17/cantor-fitzgerald-equities-analysts-decrease-earnings-estimates-for-aldeyra-therapeutics-inc-aldx.html.

Shares of Aldeyra Therapeutics (NASDAQ ALDX) traded down $0.10 during mid-day trading on Wednesday, reaching $6.10. The company had a trading volume of 85,100 shares, compared to its average volume of 297,303. Aldeyra Therapeutics has a twelve month low of $3.80 and a twelve month high of $11.90. The company has a debt-to-equity ratio of 0.02, a quick ratio of 20.35 and a current ratio of 20.35.

Aldeyra Therapeutics (NASDAQ:ALDX) last issued its quarterly earnings results on Thursday, November 9th. The biotechnology company reported ($0.32) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.41) by $0.09.

In related news, major shareholder Life Sciences Maste Perceptive acquired 200,000 shares of the firm’s stock in a transaction on Tuesday, September 19th. The stock was purchased at an average cost of $7.25 per share, with a total value of $1,450,000.00. The purchase was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders own 28.40% of the company’s stock.

Several hedge funds have recently added to or reduced their stakes in the company. Sphera Funds Management LTD. grew its holdings in Aldeyra Therapeutics by 31.0% during the second quarter. Sphera Funds Management LTD. now owns 875,931 shares of the biotechnology company’s stock valued at $4,117,000 after purchasing an additional 207,431 shares during the period. Virtu KCG Holdings LLC bought a new position in Aldeyra Therapeutics during the second quarter valued at $104,000. Perceptive Advisors LLC grew its holdings in Aldeyra Therapeutics by 6.9% during the third quarter. Perceptive Advisors LLC now owns 3,085,458 shares of the biotechnology company’s stock valued at $22,215,000 after purchasing an additional 200,000 shares during the period. Bank of New York Mellon Corp bought a new position in Aldeyra Therapeutics during the third quarter valued at $134,000. Finally, Vanguard Group Inc. grew its holdings in Aldeyra Therapeutics by 3.2% during the second quarter. Vanguard Group Inc. now owns 304,633 shares of the biotechnology company’s stock valued at $1,431,000 after purchasing an additional 9,407 shares during the period. 40.34% of the stock is owned by institutional investors.

About Aldeyra Therapeutics

Aldeyra Therapeutics, Inc, formerly Aldexa Therapeutics, Inc, is a biotechnology company. The Company’s principal activities include raising capital and research and development activities. The Company’s segment is the identification and development of a treatment for diseases related to high levels of aldehydes.

Receive News & Stock Ratings for Aldeyra Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aldeyra Therapeutics Inc. and related stocks with our FREE daily email newsletter.